Stonebridge Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Stonebridge Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,205	Closed	-$259K	–	145
2017 Q1	$259K	Buy	+8,205	New	+$243K	0.1%	105
2016 Q4	–	Sell	-7,705	Closed	-$223K	–	141
2016 Q3	$223K	Buy	+7,705	New	+$215K	0.1%	105
2016 Q2	–	Sell	-23,470	Closed	-$581K	–	149
2016 Q1	$581K	Buy	23,470 +8,277	+54%	+$227K	0.25%	68
2015 Q4	$535K	Sell	15,193 -21,245	-58%	-$569K	0.23%	79
2015 Q3	$771K	Buy	36,438 +225	+0.6%	+$5.8K	0.35%	56
2015 Q2	$1.01M	Buy	36,213 +15,083	+71%	+$425K	0.41%	55
2015 Q1	$646K	Buy	21,130 +1,755	+9%	+$55.8K	0.26%	78
2014 Q4	$620K	Sell	19,375 -7,805	-29%	-$254K	0.24%	85
2014 Q3	$769K	Sell	27,180 -2,595	-9%	-$72.3K	0.3%	67
2014 Q2	$816K	Buy	29,775 +1,025	+4%	+$27.3K	0.31%	68
2014 Q1	$757K	Buy	28,750 +9,410	+49%	+$270K	0.31%	64
2013 Q4	$566K	Buy	19,340 +700	+4%	+$22.2K	0.23%	94
2013 Q3	$570K	Buy	18,640 +6,275	+51%	+$210K	0.26%	83
2013 Q2	$392K	Buy	+12,365	New	+$406K	0.18%	115

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Stonebridge Capital Management's GHDX Position: Q2 2017 in Review

Stonebridge Capital Management sold out of Genomic Health, Inc. (GHDX) in Q2 2017, closing a stake of 8,205 shares — an estimated $259K sold.

Stonebridge Capital Management first reported a position in GHDX in Q2 2013 and held it in 14 quarters. The position peaked at $1.01M in Q2 2015. 124 funds tracked by Wall St. Rank hold GHDX as of Q2 2017.

Stonebridge Capital Management reported no remaining Genomic Health, Inc. position as of Q2 2017 after selling out during the quarter.
Stonebridge Capital Management sold 8,205 Genomic Health, Inc. shares in Q2 2017, an estimated $259K.
Stonebridge Capital Management first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 14 quarters.
Stonebridge Capital Management's Genomic Health, Inc. position peaked at $1.01M in Q2 2015.
124 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2017.

Based on Stonebridge Capital Management's 13F filing for Q2 2017, filed 27 Jul 2017.